CLXClorox Company (The)

Ticker: CLX | Current Price: $94.48 | Today's Change: +4.98%

---

What Happened

Clorox Company filed an 8-K with the SEC on November 2, 2026, disclosing its first-quarter fiscal year 2027 financial results under Items 2.02 (Results of Operations and Financial Condition) and 7.01 (Regulation FD Disclosure). For Q1 FY2027, Clorox reported net revenues of $1.429 billion and net income of $80 million, translating to both basic and diluted earnings per share of $0.65. The simultaneous filing of Item 9.01 indicates that financial statements and exhibits accompany the disclosure.

---

Why It Matters

The reported quarterly revenue of $1.429 billion and net income of $80 million provide investors with a concrete first look at how Clorox is performing heading into fiscal 2027. With the stock up nearly 5% on the day of this report, the market appears to be responding positively to the disclosed figures. The EPS of $0.65 — both basic and diluted — gives investors a clean read on per-share profitability for the quarter, an important data point as the company navigates ongoing cost pressures and a challenging consumer staples environment. Notably, the disclosed full-year FY2021 revenue figure of $5.973 billion is on record within the filing's XBRL data as a historical reference point, underscoring how the company has evolved since that period.

---

Analysis

The near-5% stock move on the day of this report suggests the Q1 FY2027 print was received as broadly reassuring by the market, at least relative to expectations. Net income of $80 million on revenues of $1.429 billion implies a net margin of roughly 5.6% for the quarter — a metric investors will want to track going forward as Clorox works to rebuild profitability following well-documented operational challenges in recent years, including supply disruptions and elevated input costs.

The $0.65 diluted EPS figure will serve as the key anchor for full-year consensus estimates, and how management frames forward guidance — in any accompanying earnings call materials — will be critical to watch. Investors following this story through StockWatch's existing initiating coverage (published September 11, 2026) will want to assess how Q1 FY2027 actuals compare against the investment thesis laid out at that time.

Key items to monitor going forward:

• Gross margin trajectory as commodity and logistics costs evolve
• Volume trends by segment, particularly in the Health & Wellness and Household segments
• Management's full-year FY2027 guidance, if updated alongside this filing
• Operating leverage: whether revenue growth, if any, is translating into disproportionate earnings improvement

At $94.48, CLX remains meaningfully below StockWatch's previously published coverage price target; the Q1 print and today's market reaction are relevant data points for that ongoing assessment, though this report makes no independent rating or target judgment.

---

Disclaimer

This report is a news and informational summary based solely on data extracted from Clorox's official SEC filing (8-K filed November 2, 2026) and publicly available market data. It does not constitute investment advice, a solicitation, or an offer to buy or sell any security. It carries no rating or price target. Investors should conduct their own due diligence and consult a qualified financial adviser before making investment decisions.

Existing Coverage

StockWatch has full coverage on CLX, published 2026-09-11. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-11-02. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/21076/000002107626000044/clx-20261102.htm